+43 664 883 16206
marion.ettenauer@orthosera.com

Albumin Bone Graft Patent Granted in the US – Important milestone in Lacerta’s IP strategy

 

Krems an der Donau, Austria, 4 September 2013 – The United States Patent Office has granted the patent entitled “Method for producing an implantable bone composition” to Lacerta Technologies Inc. The original application was submitted by the university laboratory of Dr. Lacza, founder of Lacerta Technologies, and then transferred to the company. It forms a key asset in the portfolio of 6 pending patent applications centered around the use of serum fractions for regenerative medicine applications. This original patent (US 2010/0303885) covers the use of serum albumin as an additional layer on the surface of bone grafts to improve the seeding efficiency and proliferation of bone marrow-derived mesenchymal stem cells, which results in bone healing even when regular bone grafts failed.

Krems an der Donau, Austria, 4 September 2013 – The United States Patent Office has granted the patent entitled “Method for producing an implantable bone composition” to Lacerta Technologies Inc. The original application was submitted by the university laboratory of Dr. Lacza, founder of Lacerta Technologies, and then transferred to the company. It forms a key asset in the portfolio of 6 pending patent applications centered around the use of serum fractions for regenerative medicine applications. This original patent (US 2010/0303885) covers the use of serum albumin as an additional layer on the surface of bone grafts to improve the seeding efficiency and proliferation of bone marrow-derived mesenchymal stem cells, which results in bone healing even when regular bone grafts failed.

Krems an der Donau, Austria, 4 September 2013 – The United States Patent Office has granted the patent entitled “Method for producing an implantable bone composition” to Lacerta Technologies Inc. The original application was submitted by the university laboratory of Dr. Lacza, founder of Lacerta Technologies, and then transferred to the company. It forms a key asset in the portfolio of 6 pending patent applications centered around the use of serum fractions for regenerative medicine applications. This original patent (US 2010/0303885) covers the use of serum albumin as an additional layer on the surface of bone grafts to improve the seeding efficiency and proliferation of bone marrow-derived mesenchymal stem cells, which results in bone healing even when regular bone grafts failed.

Profile Lacerta Technologies GmbH

Founded in 2012 and located in Krems an der Donau/Austria Lacerta Technologies GmbH is a development-­‐stage regenerative medicine company aiming to translate research results into products for routine clinical use. We put special emphasis on designing simple and affordable protocols allowing a wider patient population to benefit from cell therapy.
Our current development projects include an innovative albumin-­‐coated bone allograft and a point-­‐of-­‐care device for the personalized production of autologous bone grafts.

Contact information
Lacerta Technologies GmbH
Dr.-­‐Karl-­‐Dorrek-­‐Straße 23-­‐29
A-­‐3500 Krems an der Donau
Tel/Fax: +43 664 77 883 16206
Email: marion.ettenauer@lacertatech.com
www.lacertatechnologies.com

Add Your Comment

Your email address will not be published. Required fields are marked *